Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Summary

This study is a randomized ,single center clinical study which is designed to investigate whether combination of Pembrolizumab with Lenvatinib could improve pCR rate and consequent survival in resectable mucosal melanoma. All the eligible patients were assigned to receive Lenvatinib once a day (QD) for 6 weeks plus pembrolizumab on Day 1 of each 21-day cycle (Q3W) concurrently on days 1 and 22, followed by surgery and 18 cycles of Pembrolizumab 200mg q3w of adjuvant phase.

Timeline

Start

2020-12-30

Primary completion

2021-12-30

Completion

2023-12-30

Drugs

Indications